drugset / Trial / NCT06573281
A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years
RandomizedSequentialQuadruple-blindPrevention
Summary
The purpose of this study is to assess the reactogenicity, safety and immune response of various formulations of the RSV mRNA investigational vaccine administered in healthy participants 18-45 years of age.
Timeline
- Start
- 2024-09-30
- Primary completion
- 2026-04-13
- Completion
- 2026-04-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Investigational RSV vaccine 1 | Unknown | — | Intramuscular |
| Subject | Investigational RSV vaccine 2 | Unknown | — | Intramuscular |
| Subject | Investigational RSV vaccine 3 | Unknown | — | Intramuscular |
| Subject | Investigational RSV vaccine 4 | Unknown | — | Intramuscular |
| Subject | Investigational RSV vaccine 5 | Unknown | — | Intramuscular |
| Subject | Investigational RSV vaccine 6 | Unknown | — | Intramuscular |